SOPHiA GENETICS Stock
SOPHiA GENETICS S.A.
Company data
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Country
- Switzerland
- CEO
- Ross Muken
- Employees
- 415
- Market cap
- $573 M
- IPO
- 23/07/2021
SOPHiA GENETICS S.A. is a healthcare company based in Switzerland that operates within the Medical - Healthcare Information Services industry. The firm provides the SOPHiA DDM platform, which is a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
SOPHiA GENETICS stock: price history
1D
-7.7%
1W
-9.2%
1M
-15.7%
6M
+27.5%
YTD
+44.1%
1Y
+51.6%
2Y
+83.9%
5Y
-58.2%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~28% stronger price swings than usual
SOPHiA GENETICS stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
SOPHiA GENETICS S.A. is a specialized health technology provider headquartered in Switzerland. The company offers SOPHiA DDM, a cloud-based software-as-a-service platform used to analyze multimodal datasets and various diagnostic input data. Through the evaluation of this data, valuable medical insights can be generated. The platform is deployed globally by hospitals, laboratories, and companies in the biopharmaceutical industry.
- Revenue model
- Subscription
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about SOPHiA GENETICS
Analyst assessment of SOPHiA GENETICS
PRICE TARGET LOW
US$9.00
CONSENSUS
US$11.50
MEDIAN
US$11.50
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 12/10/2026
SOPHiA GENETICS stock metrics
P/E
-5.85
P/B
5.98
EV/EBITDA
-8.26
RETURN ON EQUITY
-26.9%
NET MARGIN
-95.9%
DEBT/EQUITY
0.74
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.9%
FLOAT SHARES
65,453,082
AVG. DAILY VOLUME (30D)
677,836
Insider transactions (SEC)
Menu Philippe
Camblong Jurgi
Xu Zhenyu
Puylaert Kevin
Muken Ross
Institutional holders
Comparable stocks
Frequently asked questions about SOPHiA GENETICS stock
What does SOPHiA GENETICS do?
SOPHiA GENETICS S.A. is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in Switzerland.
The CEO is Ross Muken, the company employs around 415 people.
The IPO was on 23/07/2021; the stock trades on NASDAQ under the ticker SOPH.
What do analysts say about SOPHiA GENETICS stock?
8 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$11.50, ranging from US$9.00 to US$14.00, with a median of US$11.50.
This is an external assessment, not a statement by Market Jury.
When does SOPHiA GENETICS report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 28% stronger than usual.
Does SOPHiA GENETICS pay a dividend?
No, SOPHiA GENETICS currently does not pay a dividend.
Which stocks are comparable to SOPHiA GENETICS?
Comparable stocks include Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, Evolent Health and Optima Health.
How can I get SOPHiA GENETICS stock analyzed?
Clicking "Analyze stock" lets five strategies assess SOPHiA GENETICS against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.